Starwood Hotels & Resorts Worldwide Inc. (NYSE:HOT) has announced that the Sheraton Algarve Hotel at Pine Cliffs Resort will commence a phased renovation incorporating all rooms, public areas and food and beverage outlets. Starwood Hotels & Resorts Worldwide Inc. (NYSE:HOT) net profit margin is 9.30% and weekly performance is 1.22%. On last trading day company shares ended up $79.95. Analysts mean target price for the company is $84.82. Starwood Hotels & Resorts Worldwide Inc. (NYSE:HOT) distance from 50-day simple moving average (SMA50) is 2.43%.
Olympus Corp (ADR) (OTCMKTS:OCPNY) surged after posting a doubling of its fiscal-year operating profit to 73.4 billion yen, despite at 4% fall in on-year sales. Net profit also improved to 13.6 billion yen, helped by structural reforms. Olympus Corp (ADR) (OTCMKTS:OCPNY) shares advanced 6.03% in last trading session and ended the day on $31.28.
Bruker (NASDAQ:BRKR) posted its quarterly earnings results on Wednesday. The company reported $0.11 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.09 by $0.02, American Banking and Market News reports. The company had revenue of $423.70 million for the quarter, compared to the consensus estimate of $402.04 million. During the same quarter last year, the company posted $0.08 earnings per share. Bruker Corporation (NASDAQ:BRKR) shares moved up 3.09% in last trading session and was closed at $20.69, while trading in range of $19.73 – $20.95. Bruker Corporation (NASDAQ:BRKR) year to date (YTD) performance is 4.65%.
Novo Nordisk A/S logo Novo Nordisk A/S (NYSE:NVO)’s stock had its “neutral” rating reiterated by Zacks in a note issued to investors on Monday, Analyst Ratings News reports. Novo Nordisk A/S (ADR) (NYSE:NVO) ended the last trading day at $43.90. Company weekly volatility is calculated as 1.03% and price to cash ratio as 34.60.Novo Nordisk A/S (ADR) (NYSE:NVO) showed a negative weekly performance of -0.66%.
The California-based company Halozyme Therapeutics, Inc. (NASDAQ:HALO) reported revenues for 1QFY14 at $12 million, about $0.2 million higher than the same quarter last year. Per share losses, however, widened year-over-year (YoY) from 17 cents to 22 cents for the quarter. Halozyme Therapeutics, Inc. (NASDAQ:HALO) shares advanced 2.04% in last trading session and ended the day on $7.52. HALO gross Margin is 88.70% and its return on assets is -76.60%. Halozyme Therapeutics, Inc. (NASDAQ:HALO) quarterly performance is -48.84%.
Leave a Reply